Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PIQLF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.89 Med: 12.34 Max: 45
Current: 2.89
During the past 11 years, Proteomics International Laboratories's highest Price to Tangible Book Ratio was 45.00. The lowest was 2.89. And the median was 12.34.
PIQLF's Price-to-Tangible-Book is ranked worse than 50.96% of 1148
companies
in the Biotechnology industry
Industry Median: 3.24
vs PIQLF: 2.89
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Proteomics International Laboratories Price-to-Tangible-Book Related Terms
Proteomics International Laboratories Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories Price-to-Tangible-Book Chart
PIQLF vs VRTX, REGN, RVMD: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Proteomics International Laboratories's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Proteomics International Laboratories's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Proteomics International Laboratories (PIQLF) has a Price-to-Tangible-Book of 8.67 as of Aug. 08, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Proteomics International Laboratories and its competitors. This is 30% below median its historical median of 12.34. Over the past decade, Proteomics International Laboratories' Price-to-Tangible-Book has ranged from 2.89 to 45.00. According to the industry distribution chart, Proteomics International Laboratories ranks #585 out of 1148 companies in the Biotechnology industry, placing it in the top 51%.
Is Proteomics International Laboratories' Price-to-Tangible-Book too high?
Proteomics International Laboratories' current Price-to-Tangible-Book of 8.67 is 30% below median its 10-year median of 12.34. Over the past 10 years, this metric has ranged from a low of 2.89 to a high of 45.00. The Biotechnology industry median Price-to-Tangible-Book is 3.24. Proteomics International Laboratories' value of 8.67 is 167.6% above this industry median. Based on the distribution chart, Proteomics International Laboratories ranks #585 out of 1148 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Proteomics International Laboratories has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #585 out of 1148 companies for Price-to-Tangible-Book. This places Proteomics International Laboratories in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.24. Proteomics International Laboratories' value of 8.67 is 167.6% above this benchmark. Historically, Proteomics International Laboratories' own Price-to-Tangible-Book has ranged from 2.89 to 45.00 over the past decade. While the company's 10-year median is 12.34 vs. the industry median of 3.24, Proteomics International Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.24, based on 1,148 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteomics International Laboratories's current Price-to-Tangible-Book of 8.67 is 167.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Proteomics International Laboratories and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current Price-to-Tangible-Book is 8.67, which is 30% below median its own 10-year median of 12.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Proteomics International Laboratories (PIQLF) has a current Price-to-Tangible-Book of 8.67. The stock's GF Value™ is $0.86, compared to a current price of $0.26 — trading 69.8% below its estimated fair value. The current Price-to-Tangible-Book is 8.67, which is 30% below median its 10-year median of 12.34 and 167.6% above the Biotechnology industry median of 3.24. Proteomics International Laboratories' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Proteomics International Laboratories (PIQLF), the current Price-to-Tangible-Book is 8.67 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (PIQLF) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of $0.26 is trading 69.8% below its estimated GF Value™ of $0.86.
Key valuation signals for PIQLF:
Price-to-Tangible-Book: 8.67 (30% below median its 10-year median of 12.34)
GF Value™: $0.86 vs. price of $0.26 (69.8% below fair value)
Industry Position: 167.6% above the Biotechnology median (#585 of 1148)
No single metric tells the full story. See the PIQLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
23GF Score
Get the complete analysis for PIQLF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PIQLF has been successfully added to your 
